- Report
- May 2023
- 48 Pages
United States
From €533EUR$600USD£458GBP
- Report
- May 2023
- 48 Pages
United States
From €533EUR$600USD£458GBP
- Report
- May 2023
- 48 Pages
United States
From €533EUR$600USD£458GBP
- Report
- May 2023
- 48 Pages
United States
From €533EUR$600USD£458GBP
- Report
- May 2023
- 48 Pages
United States
From €533EUR$600USD£458GBP
- Database
- December 2021
United States
From €2219EUR$2,500USD£1,910GBP
- Report
- April 2021
- 191 Pages
Global
€19528EUR$22,000USD£16,807GBP
- Report
- November 2020
- 49 Pages
Global
€1170EUR$1,318USD£1,007GBP
- Report
- August 2018
- 10 Pages
United States
From €975EUR$1,099USD£840GBP
- Report
- October 2023
- 91 Pages
Global
From €3500EUR$4,224USD£3,118GBP
- Report
- August 2024
- 102 Pages
Global
From €3500EUR$4,224USD£3,118GBP
- Book
- October 2020
- 288 Pages
- Book
- October 2019
- 632 Pages

Lung cancer is a type of cancer that originates in the lungs. It is the leading cause of cancer-related death worldwide. Oncology is the branch of medicine that deals with the diagnosis, treatment, and prevention of cancer. Lung cancer is one of the most common types of cancer treated by oncologists. Treatment options for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy.
The lung cancer market is a rapidly growing segment of the oncology market. It is driven by the increasing prevalence of lung cancer, advances in treatment options, and the increasing availability of targeted therapies. The market is expected to continue to grow in the coming years due to the increasing demand for better treatments and the development of new therapies.
Some companies in the lung cancer market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more